• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy.

作者信息

Rexer Brent N, Shyr Yu, Arteaga Carlos L

出版信息

J Clin Oncol. 2013 Jun 10;31(17):2073-5. doi: 10.1200/JCO.2012.48.5243. Epub 2013 May 6.

DOI:10.1200/JCO.2012.48.5243
PMID:23650407
Abstract
摘要

相似文献

1
Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy.磷酸酶与张力蛋白同源物缺失以及对曲妥珠单抗和化疗的耐药性。
J Clin Oncol. 2013 Jun 10;31(17):2073-5. doi: 10.1200/JCO.2012.48.5243. Epub 2013 May 6.
2
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.人表皮生长因子受体 2 过表达的局部晚期乳腺癌中磷酸酶和张力蛋白同系物缺失或磷酸肌醇-3 激酶激活以及对曲妥珠单抗或拉帕替尼的反应。
J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6.
3
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.PTEN 蛋白表达对北中央肿瘤治疗组 N9831 试验中早期表皮生长因子受体 2 阳性乳腺癌辅助曲妥珠单抗获益的影响。
J Clin Oncol. 2013 Jun 10;31(17):2115-22. doi: 10.1200/JCO.2012.42.2642. Epub 2013 May 6.
4
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.曲妥珠单抗联合依维莫司（RAD001）治疗曲妥珠单抗治疗后进展的人表皮生长因子受体 2 过表达转移性乳腺癌患者的 I/II 期研究。
J Clin Oncol. 2011 Aug 10;29(23):3126-32. doi: 10.1200/JCO.2010.32.2321. Epub 2011 Jul 5.
5
Trastuzumab and chemotherapy may be appropriate for small, node-negative, HER2-positive breast cancer.曲妥珠单抗和化疗可能适用于小肿瘤、无淋巴结转移、HER2 阳性的乳腺癌。
Oncologist. 2012;17(10):e33; author reply e34. doi: 10.1634/theoncologist.2012-0318.
6
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.新辅助抗人表皮生长因子受体2（HER2）靶向治疗对HER2阳性原发性乳腺癌的益处与10号染色体缺失的磷酸酶和张力蛋白同源物（PTEN）状态无关。
Ann Oncol. 2015 Jul;26(7):1494-500. doi: 10.1093/annonc/mdv175. Epub 2015 Apr 7.
7
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.在接受含曲妥珠单抗新辅助化疗的乳腺癌患者中，PTEN和磷酸化Akt的免疫组化表达与临床结局无关。
Med Oncol. 2009;26(3):344-9. doi: 10.1007/s12032-008-9127-2. Epub 2008 Nov 18.
8
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.拉帕替尼的抗肿瘤活性不依赖于10号染色体上缺失的磷酸酶和张力蛋白同源物，在过表达ErbB2的乳腺癌中亦是如此。
Cancer Res. 2007 Feb 1;67(3):1170-5. doi: 10.1158/0008-5472.CAN-06-2101.
9
PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.通过PTEN、Akt、MAPK、p53和p95表达来预测HER2阳性乳腺癌中曲妥珠单抗耐药性。
J BUON. 2013 Jan-Mar;18(1):44-50.
10
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.PTEN 缺失、PI3 激酶（PIK3CA）突变和 PI3K 通路激活对曲妥珠单抗治疗 HER2 阳性乳腺癌敏感性的预测作用：一项荟萃分析。
Curr Med Res Opin. 2013 Jun;29(6):633-42. doi: 10.1185/03007995.2013.794775. Epub 2013 Apr 22.

引用本文的文献

1
Mutation of PTEN: Loss and Likelihood of Being a Non-responder to Trastuzumab in a Sample of Iraqi Her2+ Breast Cancer Patients.PTEN突变：伊拉克Her2+乳腺癌患者样本中PTEN缺失及对曲妥珠单抗无反应的可能性
Cureus. 2024 Feb 23;16(2):e54765. doi: 10.7759/cureus.54765. eCollection 2024 Feb.
2
The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review.抑瘤素 M 同源物高甲基化与乳腺癌患者的相关性：荟萃分析和文献回顾。
Sci Rep. 2016 Sep 13;6:32723. doi: 10.1038/srep32723.
3
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
微小RNA-21将上皮-间质转化与炎症信号联系起来，赋予HER2阳性乳腺癌患者对新辅助曲妥珠单抗和化疗的抗性。
Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495.
4
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.PTEN缺失与HER2扩增型乳腺癌患者的不良预后相关，但与曲妥珠单抗耐药无关。
Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3.
5
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.在临床前乳腺癌模型中，CDK4/6抑制为Her2靶向治疗提供了一种有效的辅助治疗方法。
Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
6
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.乳腺癌中表皮生长因子受体/磷脂酰肌醇-3激酶/磷酸酶和张力蛋白同源物/蛋白激酶B/哺乳动物雷帕霉素靶蛋白复合物1信号通路的失调：治疗干预的可能性
Oncotarget. 2014 Jul 15;5(13):4603-50. doi: 10.18632/oncotarget.2209.
7
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.分子途径：作为癌症预后和治疗生物标志物的PI3K途径磷酸酶
Clin Cancer Res. 2014 Jun 15;20(12):3057-63. doi: 10.1158/1078-0432.CCR-12-3680.
8
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.表皮生长因子受体家族：从癌基因发现到基础科学再到基于机制的癌症治疗。
Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025.